TORONTO and WINNIPEG, June 13 /CNW/ - Cangene today reports results for the third quarter and nine months ended April 30, 2006. Revenue for the third quarter of fiscal 2006 was $28.7 million, an increase of $2.0 million or 7.7% compared to the same quarter of the prior year. Revenue for the nine months ended April 30, 2006 was $82.6 million, also up $2.0 million over same period a year ago. Revenue for the quarter increased due to completion of delivery on the U.K.-government order for Vaccinia immune globulin (“VIG”), and stronger WinRho(R) SDF sales in the U.S. following the transition in distributors from Nabi Biopharmaceuticals to Baxter Healthcare Corporation. Sales of WinRho(R) SDF in the U.S. improved markedly over the previous quarter and are approaching levels at or near those formerly achieved by Nabi.
